Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306631
Status:
COMPLETED
Last Update Posted:
2009-06-03
First Post:
2006-03-22
Brief Title:
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
Sponsor:
CASI Pharmaceuticals Inc
Organization:
CASI Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 2 study will determine the antitumor activity based on the objective rate of oral MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with advanced or metastatic breast carcinoma The study will also evaluate the safety and response duration in patients time to tumor progression and overall survival in patients following MKC-1 therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None